Exclusive Summary

• - Patent and exclusivity windows have closed globally; generics have scaled since 2017–2019, opening hospital tender and switch opportunities.
• - Clear demand: an estimated 40–60 million chemotherapy infusion episodes annually require CINV prophylaxis, covered by single-dose, long-acting palonosetron.
• - Strong guideline endorsement: preferred 5-HT3 for MEC and part of HEC triple regimens per MASCC/ESMO, NCCN and ASCO.
• - Compliance-led access: EU-GMP sterile manufacturing and USP-compliant API support registrations in EU-referenced and PIC/S markets under a distribution model.
• - Pricing edge: typical 70–90% erosion versus Aloxi enables competitive bids while maintaining sustainable supply (note: no Vietnam collaboration via China-based agency).

Asset Materials

Contact Us for Full Materials